3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
5
Phase NA
4
Phase 4
3
Phase 2
2
Phase EARLY_PHASE1
1
Phase 1/2
1
Status
Terminated
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
8
Thoracic
6
Breast
6
Other hematologic neoplasm
4
Lymphoid
3
Head & Neck
3
Plasma cell
2
Other solid neoplasm
2
Gynecologic
2
Endocrine
2
CNS
2
Other neoplasm
1
Myeloid
1
Genitourinary
1
Dermatologic
1
Conditions
Ovarian Neoplasms
1
Advanced Ovarian Cancer
1
Interventions
Paclitaxel
233
Carboplatin
217
Bevacizumab
139
Cisplatin
136
pembrolizumab
89
Gemcitabine
69
olaparib
54
Docetaxel
47
Topotecan
44
Radiotherapy
43
liposomal doxorubicin
41
Taxes
41
niraparib
38
Cyclophosphamide
36
Doxorubicin
30
Drug Therapy
29
Letrozole
28
Nivolumab
27
Magnetic Resonance Spectroscopy
25
Immunoglobulin G
25
Disulfides
24
Oxaliplatin
23
Albumin-Bound Paclitaxel
23
durvalumab
22
apatinib
21
Etoposide
21
Brachytherapy
21
lenvatinib
20
camrelizumab
20
Specimen Handling
20
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Saline Solution
×
Gynecologic
×
Clear all
NCT05794659
2023-07-20
Cornerstone4
Aston Sci. Inc.
Phase 2
Not yet recruiting
98 enrolled
NCT00738699
2017-03-30
FAR-122
Morphotek
Phase 2
Terminated
415 enrolled
11 charts